Literature DB >> 8649908

Current controversies in the management of idiopathic thrombocytopenic purpura during childhood.

D Medeiros1, G R Buchanan.   

Abstract

Both acute and chronic ITP in children are generally benign conditions. Few patients develop serious complications or long-term sequelae. Therefore, most patients require little or no specific therapy. IVIG or high-dose steroids may benefit some patients who have evidence of clinical bleeding, and splenectomy may be of value in patients with chronic ITP whose lives are altered by low platelet counts or bleeding. It is difficult to predict which patients are at risk for the development of ICH, and severe hemorrhage is not always curtailed by prior or concomitant therapy. The decision to treat a child with ITP should be based on the entire clinical picture rather than on the platelet count alone.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8649908     DOI: 10.1016/s0031-3955(05)70431-4

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  4 in total

Review 1.  Management of idiopathic thrombocytopenic purpura.

Authors:  V P Choudhry; R Kashyap; H P Pati
Journal:  Indian J Pediatr       Date:  1998 May-Jun       Impact factor: 1.967

Review 2.  Treatment of immune thrombocytopenic purpura in children : current concepts.

Authors:  Aziza T Shad; Corina E Gonzalez; S G Sandler
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

3.  Use of Recombinant Factor VIIa in a Pediatric Patient With Initial Presentation of Refractory Acute Immune Thrombocytopenic Purpura and Severe Bleeding.

Authors:  Reut Gurion; Anita Siu; Aaron R Weiss; Margaret Masterson
Journal:  J Pediatr Pharmacol Ther       Date:  2012-07

4.  Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura.

Authors:  Cindy E Neunert; George R Buchanan; Paul Imbach; Paula H B Bolton-Maggs; Carolyn M Bennett; Ellis J Neufeld; Sara K Vesely; Leah Adix; Victor S Blanchette; Thomas Kühne
Journal:  Blood       Date:  2008-08-12       Impact factor: 22.113

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.